DailyIQ
Last updated2 minutes ago

RGEN·Repligen Corporation

$175.42
+2.91 (+1.69%)
Overnight$175.42+0.00 (+0.00%)
High
$177.96
Open
$172.51
Market Cap
10.97B
52W High
$198.87
Low
$169.73
P. Close
$175.42
P/E
264.15
52W Low
$100.99
Fwd P/E
66.01
DailyIQ Est.
$206.34
Inst. Ownership
39.8%
Short Interest
12.12%
Days to Cover
6.6
Technical Score (1D)
50
NEUTRAL
News Sentiment
43
BEARISH
On Oct 13, Repligen Corporation announced that it will report its third‑quarter 2026 financial results on Oct. 27, 2026. The company said it would issue a press release before the market opens on that date. A conference call to discuss the business updates and financial results for the period ended September 30, 2026, is scheduled for 8:00 a.m. ET. No guidance or operational updates were provided beyond the scheduled release date. The announcement was made by Repligen Corporation.
LOW TARGET
$145 -17.3%
1 analysts
MEAN TARGET
$197 +12.1%
16 analysts
HIGH TARGET
$235 +34.0%
13 analysts
PRICE RANGE
$145.00 - $235.00
SB / B / H / S / SS
7/17/4/1/1
DAILYIQ EST.
$206.34 (+17.6%)
Bought (1Y)
0 shares
$0
Sold (1Y)
38,419 shares
$7.0M
Douglass Brian RobbCHIEF PRODUCT OFFICER
Award/Grant675 shares2026-10-06
Douglass Brian RobbCHIEF PRODUCT OFFICER
Award/Grant700 shares2026-10-06
Loeillot OlivierChief Executive Officer
Option Exercise4,202 shares2026-10-05
Loeillot OlivierChief Executive Officer
Sell4,202 shares2026-10-05
Loeillot OlivierChief Executive Officer
Option Exercise4,202 shares2026-10-05
77/ 100
Bullish
Overall: Bullish
✓Revenue growing year over year
✓Positive net margin
✓Positive operating cash flow
Gross Margin
52.3%
Net Margin
6.6%
Revenue CAGR
26.8%
Current Ratio
8.37x
Debt / Equity
0.26x
Return on Equity
2.3%

EPS

EstBeatMiss
$0.41$0.42$0.44$0.45$0.47Q3'25Q3'26
QtrEstActual+/−
Q3'26$0.46 - -
Q3'25$0.41$0.46+10.9%

Revenue

EstBeatMiss
$186M$193M$200M$207M$214MQ3'25Q3'26
QtrEstActual+/−
Q3'26$211M - -
Q3'25 - $189M -

Market Data

RGEN Stock Snapshot

NEUTRAL50/100
$175.42+$0.00 (0.0%)
Market cap
10.97B
P/E ratio
264.1
Day range
$169.73 – $177.96
News sentiment
43/100 · Neutral
Analyst target
$196.70 (+12.1%)
Consensus
Buy · 30 analysts
52-week range+73.7% off low · -11.8% from high
$100.99$198.87
Price $175.42 DailyIQ Est. $206.34

Neither side has the upper hand on RGEN right now, and its momentum ranks near the middle of DailyIQ's universe. Earnings and guidance carry more weight than macro data at this capitalisation.

Reverse DCF

What growth is priced into RGEN?

RICH

At today's price, Repligen Corporation needs to grow free cash flow about 60.7% a year for the next 10 years to justify its valuation at a 10.63% cost of capital. Over its actual history it has compounded free cash flow at 26.0% a year, so the market is asking for 34.6 percentage points above its own delivered rate. On that basis RGEN looks priced above what its own growth record supports.

Implied FCF growth
60.7%
Historical FCF CAGR
26.0%
Growth gap
+34.6 pts
Verdict
RICH
Discount rate (WACC)
10.63%
Beta
1.15

Behaviour On Record

What RGEN's own history says about today's numbers

Realized volatility (21d)
57.2% 80th pct
Below its peak
-46.8%
vs 200-day average
+21.9%
Up days (1y)
54%

Repligen Corporation is currently running 57.2% annualised volatility over the last 21 sessions. Measured against RGEN's own 13 years of daily returns rather than a market-wide average, that is the 80th percentile — elevated for this stock, against a typical reading of 42.9%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.

RGEN is trading -46.8% below its running peak. Across 12 full years on file, its median worst-drawdown-in-a-year was -29.7%, and the deepest was -45.5% in 2022. The current drawdown is already deeper than this stock's typical annual low point, which puts it in the part of its range where past recoveries began — and where past declines also continued.

Price sits +21.9% from its 200-day moving average. Against every other day in its history, that gap ranks at the 76th percentile — a somewhat wider gap than its own norm. Over the past year RGEN closed higher on 54% of sessions, and it is currently 1 session into a rising streak.

On October specifically: over 13 years of records, RGEN finished the month higher 7 of 13 times, with a median return of +2.2% and an average of +2.9%. Its strongest month historically has been July at +8.4% on average, its weakest September at -3.3%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.

Overnight risk is measurable too: RGEN has opened more than 2% away from the prior close in 272 of 3,267 sessions (8.3% of the time), with the largest gaps running +28.0% and -10.6%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.

All figures computed from 3,268 daily closes between 2013-10-15 and 2026-10-13, split-adjusted, recomputed daily. Percentiles are against RGEN's own 13-year history, not a peer group or index.

Sector Rotation

Is money rotating into or out of RGEN's sector?

Repligen Corporation sits in the Health Care sector, currently ranked 4th of 12 GICS sectors by relative-strength rotation score (improving). Within its narrower Biotechnology industry group, RGEN ranks 11th of 15 tracked industries, lagging.

Sector rank
#4 of 12
Sector state
Improving
Sector rotation score
82
Industry rank
#11 of 15

Options Market

What is the options market pricing for RGEN?

CallsPuts

For Repligen Corporation's nearest expiry (2026-10-16, 2 days out), open interest is call-heavy, a bullish tilt (put/call ratio of 0.70), with at-the-money implied volatility around 0.8%. The options market is pricing roughly a ±0.1% move by that expiry — a range of about $172.72–$172.92.

Put/call ratio (2026-10-16)
0.70
ATM implied volatility
0.8%
Total open interest
4,536
Expected move by 2026-10-16
±0.1% ($172.72–$172.92)

Analyst Rating Changes

Are analysts turning bullish or bearish on RGEN?

Barclays most recently reiterated its rating on Repligen Corporation to Overweight on Oct 7, 2026 with a price target of $225 (from $175). Over the last 90 days, coverage has run 0 upgrades against 0 downgrades, a net mixed lean.

Latest action
Barclays — Overweight
90-day upgrades
0
90-day downgrades
0
Net rating momentum
0
DateFirmActionRatingPrice target
Oct 7, 2026BarclaysMaintainedOverweight$175 → $225
Sep 9, 2026UBSMaintainedBuy$195 → $225
Jul 30, 2026Wells FargoMaintainedOverweight$180 → $185
Jul 29, 2026JP MorganMaintainedOverweight$165 → $175
Jul 7, 2026BenchmarkUpgradeHold → Buy$185
Jul 6, 2026Evercore ISI GroupMaintainedOutperform$150 → $160
Jun 3, 2026HSBCMaintainedBuy$170 → $150
May 6, 2026JP MorganMaintainedOverweight$180 → $165
May 6, 2026BarclaysMaintainedOverweight$145 → $160
Apr 20, 2026Canaccord GenuityMaintainedHold$165 → $145
Apr 17, 2026Roth CapitalInitiatedBuy$160
Apr 14, 2026BarclaysMaintainedOverweight$175 → $145

ETF holders

ETFs holding RGEN

News Sentiment Analysis

Sentiment gathered from recent headlines

43/100
Strong NegativeNeutralStrong Positive
BEARISH

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles
What did this article say?
Repligen Corporation confirmed that its third‑quarter 2026 financial results will be reported on October 27, 2026. The company will issue a press release before the market opens and hold a conference call at 8:00 a.m. ET to discuss the results for the period ended September 30, 2026. No additional operational or financial guidance was disclosed.
What did this article say?
Barclays analyst Luke Sergott upgraded Repligen (NASDAQ:RGEN) to an Overweight rating on October 7, raising the price target from $175 to $225. The move reflects confidence in the company’s growth prospects and recent operational performance. The new target represents a significant upside potential for investors, signaling a bullish stance from a major research house.
What did this article say?
On October 5, 2026, Repligen CEO Olivier Loeillot sold 5,535 shares for $1,036,654, reducing his holdings to 45,788 shares. The transaction was reported in a Form 4 filing with the SEC. The sale may signal a lack of confidence in the company’s near‑term prospects, potentially impacting investor sentiment.
What did this article say?
Repligen (RGEN) announced on October 6 that it had closed its acquisition of BioLife Solutions (BLFS). Shareholders of BioLife received $11.25 in cash and 0.1442 shares of RGEN common stock per share, with cash used to replace fractional shares. The deal is expected to broaden RGEN’s global footprint and enhance its cell‑therapy portfolio, with detailed financial impact to be disclosed in the upcoming Q3 earnings call. RGEN shares fell 3% in early trading following the announcement.
What did this article say?
Repligen Corporation completed its acquisition of BioLife Solutions on October 6, 2026, adding BioLife’s cell processing tools and services to its portfolio. The deal enhances Repligen’s presence in the growing cell and gene therapy market, providing a high‑margin consumables business with recurring revenue. Integration plans were already underway, positioning the combined entity to support customers across critical stages of the cell therapy workflow.
What did this article say?
Repligen Corporation announced that it will acquire BioLife Solutions, a move that is expected to close soon pending final conditions. The acquisition positions RGEN to expand its product portfolio and strengthen its market presence in the biopharmaceutical sector. The deal is anticipated to generate additional revenue streams and enhance RGEN’s competitive standing. Investors viewed the announcement favorably, reflecting confidence in the strategic fit and potential upside. The transaction is expected to be completed before the end of the fiscal year.
What did this article say?
RGEN closed up 2% on September 29 after reporting a strong second‑quarter 2026 earnings beat and raising its full‑year guidance. The company also announced an expansion into cell therapy, adding a new revenue stream. These developments reinforced investor confidence and pushed the stock to a fresh 52‑week high.
What did this article say?
Repligen Corporation (RGEN) published a slide deck in conjunction with the Wells Fargo 21st Annual Healthcare Conference, providing no new financial or operational data.
What did this article say?
Repligen’s adjusted operating margin has fallen 16.2 percentage points over five years, raising concerns about rising costs and shrinking profitability. Despite recent stock gains, analysts highlight a deteriorating expense base that could limit future growth. The report cautions investors that the company’s momentum may not sustain without a turnaround in margin performance.
What did this article say?
Repligen Corporation (RGEN) participated in the Wells Fargo 21st Annual Healthcare Conference, where CEO Olivier Loeillot and CFO Jason Garland discussed the company’s organic growth trajectory and strategic priorities. The executives emphasized a 13% growth rate in the second quarter and outlined initiatives aimed at sustaining momentum. While no new financial guidance was released, the presentation reinforced RGEN’s focus on expanding its product portfolio and strengthening client relationships.

Technical Analysis

Real-time indicators across multiple timeframes

50
NEUTRAL
Momentum rank against about 1,000 stocks and ETFs for this timeframe.
Unlock full technicals
Create a free account to access more indicators and deeper timeframe data.
Institutional & Hedge Fund Ownership
25 tracked managers · $3.51B combined position · 11 adding, 14 trimming, 0 unchanged (latest 13F filings)
ManagerTrendShares Held% of Co.Position ValueFiled
Vanguard Group Inc▼ Sell4,993,9457.98%$818.31M2026-01-29
BlackRock, Inc.▼ Sell5,384,9388.61%$734.72M2026-08-07
FMR LLC (Fidelity)▲ Buy3,326,6905.32%$453.89M2026-08-13
Maverick Capital Ltd▲ Buy1,984,5543.17%$270.77M2026-08-14
Invesco Ltd.▲ Buy1,387,2422.22%$189.28M2026-08-14
Geode Capital Management, LLC▼ Sell1,062,4761.70%$145.00M2026-08-12
Goldman Sachs Group Inc▲ Buy965,4111.54%$131.72M2026-08-14
William Blair Investment Management, LLC▲ Buy788,5711.26%$107.59M2026-08-12
AllianceBernstein L.P.▼ Sell795,2821.27%$93.70M2026-08-14
Norges Bank▲ Buy575,2260.92%$78.48M2026-08-12
Morgan Stanley▼ Sell543,2420.87%$74.12M2026-08-13
Northern Trust Corp▼ Sell444,1460.71%$60.60M2026-08-13
JPMorgan Chase & Co▲ Buy427,7700.68%$58.95M2026-08-12
Bank of America Corp▲ Buy426,2910.68%$58.16M2026-08-14
Citadel Advisors LLC▼ Sell376,3090.60%$51.34M2026-09-02
Balyasny Asset Management L.P.▲ Buy355,5070.57%$48.51M2026-08-14
Marshall Wace, LLP▼ Sell282,1070.45%$38.49M2026-08-13
Point72 Asset Management, L.P.▼ Sell166,1570.27%$22.67M2026-08-14
Loomis Sayles & Co L P▼ Sell148,6760.24%$20.29M2026-08-14
Gotham Asset Management, LLC▲ Buy142,6130.23%$19.46M2026-08-14
D. E. Shaw & Co., Inc.▼ Sell83,3280.13%$11.37M2026-08-14
Verition Fund Management LLC▲ Buy37,9960.06%$5.18M2026-08-14
Moore Capital Management, LP▼ Sell37,5490.06%$5.12M2026-08-14
Wells Fargo & Company▼ Sell33,7150.05%$4.60M2026-08-14
Susquehanna International Group, LLP▼ Sell21,7210.03%$2.96M2026-08-14
Q2 2026 flow:2.31M sh bought ($315.82M)2.45M sh sold ($333.70M)net -139.0K sh (−$17.88M)
Congressional Trading Activity
4 disclosed trades · ~$56.5K est. traded value · 2 buys, 2 sells
MemberChamberStateTypeAmountTradedFiled
Lisa McClainHouseMI09▲ Buy$1K - $15K2025-10-302025-11-21
Lisa McClainHouseMI09▼ Sell$1K - $15K2025-06-172025-08-13
Lisa McClainHouseMI09▲ Buy$1K - $15K2025-06-112025-08-13
Jefferson ShreveHouseIN06▼ Sell$15K - $50K2025-04-072025-05-08